View Rule
HHS/FDA | RIN: 0910-AC30 | Publication ID: Fall 2007 |
Title: Medical Devices; Anesthesiology Devices; Proposed Reclassification of Pressure Regulators for Use With Medical Oxygen and Separate Classification of Oxygen Conserving Devices | |
Abstract: The Food and Drug Administration (FDA) is proposing to reclassify pressure regulators for use with medical oxygen from class I to class II, establish a separate classification for oxygen conserving devices, and establish a special control for these devices to address problems of fire and explosion associated with use of these devices. The special control would be a guidance document that includes standardized testing, performance, and labeling guidance for industry. Devices that meet the standard identified in the special controls guidance document would be exempt from the premarket notification requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The requirements of the proposed rule would be phased-in to minimize the cost of complying with the special control. | |
Agency: Department of Health and Human Services(HHS) | Priority: Routine and Frequent |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Long-Term Actions |
Major: No | Unfunded Mandates: No |
CFR Citation: 21 CFR 868.2700; 21 CFR 868.2750; 21 CFR 868.5905; 21 CFR 5910 (To search for a specific CFR, visit the Code of Federal Regulations.) | |
Legal Authority: 21 USC 351; 21 USC 360; 21 USC 360(c); 21 USC 360e; 21 USC 360j; 21 USC 371 |
Legal Deadline:
None |
||||||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: Undetermined | Government Levels Affected: Undetermined |
Federalism: Undetermined | |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: Myrna Hanna Regulations Staff Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health (HFZ-215), 1350 Piccard Drive, PI50 RM150F, Rockville, MD 20850 Phone:240 276-2347 Fax:240 276-2352 Email: myrna.hanna@fda.hhs.gov |